KKR to invest $200 million in drugmaker Gland Pharma

Thu Nov 28, 2013 1:44pm IST

An art handler places drugs for an art installation in the new Brandhorst modern art museum in Munich, May 6, 2009. REUTERS/Alexandra Beier/Files

An art handler places drugs for an art installation in the new Brandhorst modern art museum in Munich, May 6, 2009.

Credit: Reuters/Alexandra Beier/Files

Related Topics

Stocks

   

REUTERS - U.S. buyout firm KKR & Co LP(KKR.N) has agreed to invest about $200 million in drugmaker Gland Pharma Ltd, marking the largest private equity investment in the local pharmaceutical sector amid growing demand for generic drugs in overseas markets.

Under the deal, KKR will acquire a minority holding in Gland Pharma, including the stake held by private equity fund Evolvence India Life Science Fund, KKR said in a statement on Thursday. The size of the stake was not disclosed.

KKR'S latest investment in India underscores the positive outlook for generic drugmakers, despite some concerns about manufacturing quality after the recent crackdown by overseas regulators including the U.S. Food and Drug Administration.

Private equity firm Actis last month invested $48 million in Symbiotec Pharmalab Ltd, a producer of steroid-hormone active pharmaceutical ingredients in India.

Indian drugmakers are among the world's biggest producers of cheap generic medicines, as developed nations battle rising healthcare costs and big-selling drugs going off-patent in the lucrative U.S. market.

The rise in demand for generic drugs has led to closer regulatory scrutiny and a rash of sanctions imposed on top drugmakers including Ranbaxy Laboratories Ltd (RANB.NS) and Wockhardt Ltd (WCKH.NS).

Gland Pharma develops and manufactures generic injectables primarily for selling in the U.S. market and also for India and some other markets.

KKR's investment in Gland, which is subject to regulatory approvals, will represent the New York-based firm's second private equity transaction in India this year. KKR has invested about $1 billion in companies in Asia over the last two months.

KKR's investment in Gland represents its fourth announced investment from its $6 billion Asia fund, which it raised in July to deploy more capital in emerging markets where slowing economic growth has cut overall company valuations.

Private equity investments in India fell 67 percent in the July-September quarter from a year earlier to about $1.3 billion, according to data from sector tracker Venture Intelligence.

(Reporting by Indulal PM in MUMBAI; Writing by Sumeet Chatterjee; Editing by Matt Driskill)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Literary Giant Dies

Literary Giant Dies

Nobel winner Garcia Marquez, master of magical realism, dies at 87.  Read 

Election 2014

Election 2014

India holds biggest day of voting with BJP gaining strength  Full Article | Full Coverage 

Insider Trading

Insider Trading

Ex-Goldman director Gupta starts prison term on June 17.  Full Article 

Market Eye

Market Eye

Sensex jumps 351 points, snaps 3-day losing streak  Full Article 

Expansion Plans

Expansion Plans

Reliance Industries, HPCL Mittal plan refinery expansions.  Full Article 

S&P on India

S&P on India

S&P: India's ratings to depend on next govt econ, fiscal policies.  Full Article 

Ambitious Aim

Ambitious Aim

In green car race, Toyota adds muscle with fuel-cell launch.  Full Article 

Deal Talk

Deal Talk

Piramal to buy 20 percent stake in Shriram Capital for $334 million.  Full Article 

Bond Market

Bond Market

A star abroad, RBI boss riles bond traders at home  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage